Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Benoit You
Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian Cancer : A Review
1Medical Oncology, Lyon University Hospital, EPSILyon, Lyon, France 2CICLY, Claude Bernard University Lyon 1, University of Lyon, Lyon, France 3GINECO, Paris, France 4The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom 5Fred & Pamela Buffett Cancer Center at Nebraska Medicine, Omaha 6Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada 7Department of Obstetrics and Gynecology, Hillel Yaffe...
Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors : The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial
|
Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial Supplement 1. Trial Protocol and Statistical Analysis Plan Supplement 2. eTable 1. FIGO score items of enrolled patients eTable 2. hCG normalization across subgroups defined by disease stage, FIGO score, and concomitant treatments of interest Supplement 3. Figure 1.
By Benoit You, Jean-Pierre Lotz, Pierre Descargues, Florence Joly, Coriolan Lebreton, Laurence Gladieff, Philippe Follana, Jérome Massardier, Touria Hajri, Sylvie Bin, Fabien Subtil, Christophe Desauw, Magali Provansal, Vérane Schwiertz, François Golfier, Pierre-Adrien Bolze, Mathieu Jamelot, Adrien Msika, Marine Alves-Ferreira, Carole Langlois-Jacques, Adeline Roux
|
JAMA Oncology
Verified
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial - Nature Communications
Abstract Single-agent maintenance poly(ADP-ribose) polymerase (PARP) inhibition may represent an effective strategy in patients with advanced/metastatic endometrial cancer responding to platinum-based chemotherapy, including for molecular subtypes with suboptimal options. To explore this approach, we initiated the randomized phase IIb UTOLA trial (NCT03745950).
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial - Nature Cancer
Abstract Immune checkpoint inhibitors improve the treatment of many solid tumors and have shown encouraging results in advanced squamous cell carcinoma (SCC), yet only a minority of patients respond to immune checkpoint inhibitor monotherapy. We conducted the PEVOsq trial, an open-label, nonrandomized, multicenter, basket phase 2 trial to evaluate the combination of pembrolizumab and vorinostat in recurrent/metastatic SCC of various origins.
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib - Genome Medicine
AB: Conceptualization, methodology, formal analysis, visualization, resources, writing – original draft, writing – review & editing. IR-C: Resources, writing – original draft, writing – review & editing. ER: Resources, writing – original draft, writing – review & editing. KC: Resources, writing – original draft, writing – review & editing. FS: Resources, writing – original draft, writing – review & editing. CA: Resources, writing – original draft, writing – review & editing.
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer - British Journal of Cancer
|
Abstract High-grade serous ovarian cancer (HGSOC) can be treated with platinum-based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS). Histopathological response to NACT can be assessed using Böhm’s chemotherapy response score (CRS). We investigated whether germline BRCA1/2 (gBRCA1/2) genotype associated with omental CRS phenotype.
By Robert Morgan, Bethany Barnes Verified, Helene Schlecht, George J. Burghel, Andrew Clamp, Richard Edmondson Verified, Benoit You, Gordon C Jayson
|
Nature
Verified
Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma
Low grade serous ovarian carcinoma (LGSOC) accounts for 2.5% of all ovarian carcinoma more affects younger women than high grade serous ovarian carcinoma. Hysterectomy is performed routinely for LGSOC treatment, but fertility sparring surgery (FSS) is feasible for some early stages. Currently, there is no study about uterine involvement in LGSOC. We evaluate uterine involvement in LGSOC patients and aim to identify pre-operative predictive factors.
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study | Journal of Clinical Oncology
Assessment of the Prognostic and Predictive Values of KELIM Regarding PFS and OS The main objective was to confirm a benefit in OS with bevacizumab addition in patients with a high-risk disease characterized by an unfavorable KELIM, as suggested in the ICON-7 trial. The prognostic value of KELIM score for PFS and OS was assessed using univariate and multivariate tests (C-index, Kaplan-Meier method, log-rank, and Cox model).
Genomics to select treatment for patients with metastatic breast cancer - Nature
Abstract Cancer progression is driven in part by genomic alterations1. The genomic characterization of cancers has shown interpatient heterogeneity regarding driver alterations2, leading to the concept that generation of genomic profiling in patients with cancer could allow the selection of effective therapies3,4. Although DNA sequencing has been implemented in practice, it remains unclear how to use its results.
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study
Platinum-based chemotherapy followed by maintenance treatment with bevacizumab and/or poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPis) is the standard first-line systemic treatment for patients with high-grade carcinomas of the ovary, fallopian tube, or peritoneum (high-grade ovarian carcinomas [HGOC]).1-6 Which patients truly benefit from PARPi maintenance remains controversial.
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas
Highlights • In ovarian cancer patients, the 1st-line treatment relies on surgery and chemotherapy. • The prognostic role of the chemotherapy efficacy has been insufficiently addressed. • Indicators of the chemosensitivity include pathological, genomic or circulating markers. • Both the surgery completeness and chemosensitivity impact the treatment success. • The debulking surgery utility may differ according to the primary chemosensitivity.
Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial
Patients diagnosed with low-risk gestational trophoblastic tumors (GTT), which represent approximately 95% of malignant gestational trophoblastic disease forms (including invasive mole, choriocarcinoma, epithelioid trophoblastic tumors, and placental site trophoblastic tumors), have International Federation of Gynecology and Obstetrics (FIGO) 2000 risk scores ranging from 0 to 6 and are treated with single-agent chemotherapy.1,2 In Europe, the 8-day methotrexate protocol (modified by Bagshawe...
Benoit You, MD, PhD, on the use of Avelumab to Treat Patients With Gestational Trophoblastic Tumors
A small, phase II study presented at the ASCO 2020 Virtual Scientific Program found that avelumab (Bavencio) demonstrated the potential to cure 53% of patients with gestational trophoblastic tumors (GTT) who were resistant to single-agent chemotherapy. In an interview with CancerNetwork, lead study author Benoit You, MD, PhD of the Centre Hospitalier Lyon-Sud and Lyon Investigational Center for Treatments in Oncology and Hematology, discussed the study and some key results from it.
The official French guidelines to protect patients with cancer against SARS-CoV-2 infection
On request of the French Health Ministry, the French High Council for Public health (Haut Conseil de Santé Publique [HCSP]) entrusted a representative group of French medical oncologists and radiation oncologists, working across academic and private practice, with the task of preparing guidelines to protect patients with cancer against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, while maintaining the possibility of cancer treatment.
CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial
Research Article Benoît You, Patrick ROBELIN, Michel Tod, Christophe Louvet, Jean-Pierre Lotz, Sophie Abadie-Lacourtoisie, Michel Fabbro, Christophe Desauw, Nathalie Bonichon-Lamichhane, Jean-Emmanuel Kurtz, PHILIPPE FOLLANA, Marianne Leheurteur, Francesco Del Piano, Gwenael Ferron, Gaëtan DE RAUGLAUDRE, Isabelle Ray-Coquard, Pierre Combe, Annick CHEVALIER PLACE, Florence Joly, Alexandra Leary, Eric Pujade-Lauraine, Gilles Freyer and Olivier Colomban DOI: 10.1158/1078-0432.CCR-20-0054...
In Silico Evaluation of Pharmacokinetic Optimization for Antimitogram-Based Clinical Trials
AbstractAntimitograms are prototype in vitro tests for evaluating chemotherapeutic efficacy using patient-derived primary cancer cells. These tests might help optimize treatment from a pharmacodynamic standpoint by guiding treatment selection. However, they are technically challenging and require refinements and trials to demonstrate benefit to be widely used.
In silico evaluation of pharmacokinetic optimization for antimitogram-based clinical trials
AbstractAntimitograms are prototype in vitro tests for evaluating chemotherapeutic efficacy using patient-derived primary cancer cells. These tests might help optimize treatment from a pharmacodynamic (PD) standpoint by guiding treatment selection. However, they are technically challenging and require refinements and trials to demonstrate benefit in order to be widely used.
First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers
YS110 is well tolerated up to 6?mg?kg -1 Q1W, which has been defined as the RP2D, with encouraging prolonged disease stabilisations observed in a number of patients with advanced/refractory mesothelioma. Thirty-three patients (22 mesothelioma) received a median of 3 (range 1–30) YS110 infusions across six dose levels (0.1–6?mg?kg -1 ). MTD was not reached and two dose-limiting toxicities (infusion hypersensitivity reactions) led to the institution of a systemic premedication.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Benoit
Contact Benoit, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack